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ABSTRACT 
 
Objectives 
Evaluate long-term effectiveness and tolerability of brivaracetam in clinical practice in patients with 
focal epilepsy. 
 
Materials and Methods 
This was a multicentre retrospective study. Patients aged ≥16 years were started on brivaracetam 
from November 2016 to June 2017 and followed over 1 year. Data were obtained from medical 
records at 3, 6 and 12 months after treatment initiation for evaluation of safety- and seizure-related 
outcomes. 
 
Results 
575 patients were included in analyses; most had been treated with ≥4 lifetime antiepileptic drugs. 
Target dosage was achieved by 30.6% of patients on the first day. Analysis of primary variables at 12  
months revealed that mean reduction in seizure frequency was 36.0%, 39.7% of patients were ≥50% 
responders and 17.5% were seizure-free. Seizure-freedom was achieved by 37.5% of patients aged 
≥65 years. Incidence of adverse events (AEs) and psychiatric AEs (PAEs) were 39.8% and 14.3%, 
respectively, and discontinuation due to these were 8.9% and 3.7%, respectively. Somnolence, 
irritability and dizziness were the most frequently reported AEs. At baseline, 228 (39.7%) patients 
were being treated with levetiracetam; most switched to brivaracetam (dose ratio 1:10–15). Among 
those who switched because of PAEs (n=52), 9 (17%) reported PAEs on brivaracetam, and 3 (3.7%) 
discontinued because of PAEs. Tolerability was not highly affected among patients with learning 
disability or psychiatric comorbidity. 
 
Conclusions  
In a large population of patients with predominantly drug-resistant epilepsy, brivaracetam was 
effective and well-tolerated; no unexpected AEs occurred over 1 year and the incidence of PAEs was 
lower compared with levetiracetam. 
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INTRODUCTION 
Introduction of new antiepileptic drugs (AEDs) expands the pool of available options, increasing the 
potential for patients with drug-resistant epilepsy (DRE) to achieve seizure control. This group 
carries the major burden of epilepsy, with increased rates of cognitive and behavioural problems, 
comorbidities, and reduced quality of life.1 
 
Brivaracetam (BRV), one of the most recent AEDs to become available, is a synaptic vesicle 2A (SV2A) 
ligand with a 10- to 30-fold increased affinity for SV2A compared with levetiracetam (LEV), the first 
AED to be shown to act via this mechanism.2 The two AEDs bind to different sites on SV2A and at 
therapeutically relevant concentrations, BRV has no effect on ligand-gated receptors or voltage-
gated potassium and calcium channels.3–5  This mechanistic divergence between the two may explain 
the differences in outcomes observed in clinical trials. 
 
In three Phase III, randomised controlled trials (RCTs), adjunctive therapy with BRV reduced focal 
seizure frequency and was associated with a favourable safety profile.6–8 Full characterisation of the 
clinical profile of a new drug however, necessitates analysis of data from clinical practice, beyond 
the confines of clinical trials that stipulate strict inclusion/exclusion criteria. Several real-life BRV 
studies have been reported; however, most had small sample sizes and short follow-ups.9–14 
 
The main objective of the study reported here was to evaluate the effectiveness and tolerability of 
BRV over a 1-year period in a large population of patients with focal epilepsies. Further objectives 
were to compare responses in particular patient subgroups, including those previously treated with 
LEV. 
 
MATERIAL AND METHODS 
BRIVA-LIFE (Brivaracetam in real-life setting) was a 1-year, retrospective study conducted across 18 
centres. The study was approved by the ethics committee of La Fe University Hospital, Valencia, 
Spain, and following protocol, patients and/or their caregivers provided written informed consent 
for the use of anonymised data in their medical records. The study is reported according to STROBE 
guidelines.15 
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Study participants 
Records of patients attending participating centres starting November 2016 were screened. Patients 
≥16 years of age were included if they had focal epilepsy, and received treatment with BRV starting 
≥1 year before database close (June 2018). Exclusion criteria included history of alcoholism or drug 
abuse in the previous year, and enrolment in other studies with AEDs or medical devices. 
 
Data collection 
At baseline, physicians recorded demographics, seizure type, aetiology, previous/concomitant AEDs, 
presence of learning disability (LD), and medical/psychiatric comorbidities, and if applicable, the 
reason for switching from LEV to BRV. Classification was based on International League Against 
Epilepsy 1981 and 2017 terminology.16,17 
 
At 3-, 6- and 12-month visits – standard practice when initiating a new AED – physicians recorded 
seizure frequency, BRV dose, and adverse events (AEs). Information was obtained from patients’ 
seizure diaries (transcribed to clinical charts) and directly from patient/caregiver interviews. All 
patients had at least one blood test (complete blood count and biochemistry) over the 1-year 
observation period. 
 
Study variables 
Primary endpoints for evaluating effectiveness were seizure-freedom, patients with ≥50% reduction 
in seizure frequency from baseline (responders), and percentage seizure reduction from baseline at 
12 months. Further analyses were conducted using data from the 3- and 6-month visits. Seizure-
freedom at each time point was defined as no seizures since the previous visit – at 12 months, it was 
defined as no seizures during the preceding 6 months, and at 3 and 6 months defined as no seizures 
since baseline or the 3-month visit, respectively. Seizure reduction measures were based on monthly 
seizure frequency. Baseline seizure frequency was defined as the mean number of seizures/month 
during the 3-month period before BRV initiation. If no seizures were reported at this time, the 
baseline period was extended to the previous 12 months. 
 
Safety end-points were incidences of, and discontinuations due to AEs as the main reason. Only AEs 
considered by participating physicians to be BRV-related were included in the analysis and were 
classified as mild, moderate or severe.  
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Exploratory analysis were performed to evaluate the impact of previous LEV exposure and the 
switch from LEV to BRV, as well as impact of age, LD or medical/psychiatric comorbidity on 
outcomes.  
 
The safety set included all patients who received ≥1 BRV dosage; those who also had ≥1 seizure-
related assessment during the 12 months after initiating BRV constituted the analysis set. Seizure-
related outcomes were analysed using data from the analysis set, based on the last observation 
carried forward.  
 
Statistical analysis 
A descriptive analysis of all variables was conducted. Change in seizure frequency from baseline was 
analysed using the Wilcoxon test. For subgroup analyses, baseline characteristics were compared 
using the Mann-Whitney U test for quantitative and the chi-square test for qualitative variables. The 
Mann-Whitney U test was used to compare percentage reduction in seizure frequency, and the chi-
square test to compare 100% (seizure-freedom) and 50% response rates. For safety analyses, AEs 
and their intensity were described by absolute frequencies and percentages. A binary logistic 
regression analysis was performed to identify factors predictive of seizure-freedom at the end of the 
observation period (methodology and results in supplementary material). The level of significance 
was set at 5%. SPSS version 19.0 was used for all analyses. 
 
RESULTS 
Of 636 patients, 575 (90.4%) met the inclusion criteria; most exclusions were due to follow-up <1 
year (Figure S1). All included patients received ≥1 dose of BRV (safety set), and 572 had ≥1 seizure-
related assessment (analysis set). Retention rate at 3, 6 and 12 months was 90.8%, 80.2% and 70.4%, 
respectively. Most frequent reasons for discontinuation were AEs (8.9%), lack of efficacy (12.3%), 
and a combination of both (7.5%). Most patients had been treated with ≥4 lifetime AEDs, indicating 
that a large proportion had DRE (Table 1).  
 
Treatment profile 
Mean retention time on BRV was estimated to be 11 months (95% confidence interval 10.6, 11.4) 
using the Kaplan-Meier approach. Mean (SD) BRV dose was 66.9±47 mg (median 50 mg, range 25–
200 mg) on the first day, 131.6±54.8 mg (100 mg, 15–300 mg) at 3, 153.2 ± 60.7 mg (150 mg, 25–400 
mg) at 6, and 160.9±59.9 mg (187.5 mg, 25–350 mg) at 12 months. Target dosage was achieved by 
30.6% of patients on the first day; for the remainder, titration to full therapeutic dose lasted a mean 
of 18.9 days (range 3–70). Most frequent titration schedule was 25–50 mg/week (44.6%). 
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The main reasons for initiating BRV were inadequate seizure control (n=466, 81.1%), inadequate 
seizure control combined with poor tolerability (n=64, 11.1%), and poor tolerability (n=42, 7.3%). 
Patients were on a median of three concomitant AEDs at baseline and two at the 12-month visit 
(p<0.001; Figure S2). At the end of follow up, 21 patients (3.7%) were on monotherapy. 
 
Primary variables 
Effectiveness 
At 12 months, mean and median reduction in seizure frequency was 36.0% and 50.7%, respectively 
(p<0.001). Mean seizure reduction was 61.6% (median 100%) for simple partial seizures (focal with 
retained awareness), 37.9% (82.5%) for complex partial seizures (focal with impaired awareness), 
and 25.3% (88.7%) for secondary generalised seizures (focal to bilateral tonic-clonic). Seizure-
freedom was observed in 17.5% of patients and 39.7% were responders; 12.6% reported worsening 
(Figure 1). Thirteen patients were seizure-free at baseline and 11/13 remained so over the follow-
up. Better responses were observed in the early add-on setting – patients with fewer lifetime AEDs 
were more likely to achieve seizure-freedom, although some patients treated with 12 AEDs also 
responded (Figure 2).  
 
Safety and tolerability 
At 12 months, 39.8% of patients had reported 1 AE, and 14.3% 1 psychiatric AE (PAE); 8.9% and 
3.7% had discontinued due to AEs and PAEs, respectively (Table 2). Most AEs were mild or moderate 
in intensity. Most frequent AEs were somnolence, irritability and dizziness (Table 3). The most 
frequent PAE was irritability (6.2%). 
 
Exploratory analyses 
Previous levetiracetam exposure 
At baseline, 106 patients (20.2%) were LEV-naïve. Seizure-freedom was achieved by more LEV-naïve 
patients at 3 (26.0% vs 12.0%), 6 (23.6% vs 11.1%) and 12 months (17.9% vs 13.4%) than those with 
previous exposure (difference significant at 3 and 6 months; both p=0.001). Incidence of AEs at 12 
months was similar; 40.6% in the LEV-naïve group and 39.4% in the group with previous exposure.  
 
Among 347 (60.9%) patients not on LEV at baseline, 236 (73.3%) underwent BRV dose titration while 
86 (26.7%) achieved target dosage on the first day (schedule unknown for 25 patients). At 3 months, 
the proportion of seizure-free patients was significantly greater in those reaching target dosage on 
first day than in the titration group (25.6% vs 15.7%; p=0.044), while the proportion of patients 
reporting AEs (32.6% vs 28.0%) was similar. Among patients starting BRV due to poor seizure control 
(n=315), 84 (26.7%) achieved target dosage on the first day, and 231 (73.3%) underwent dose 
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titration. At 3 months, the proportion of seizure-free patients was significantly greater in the non-
titration than in the titration group (23.8% vs 14.3%; p=0.048). 
 
Switch from LEV to BRV 
Most patients (223/228) taking LEV at baseline switched to BRV; predominantly due to poor efficacy 
(n=145, 65%), followed by a combination of poor efficacy and AEs (41, 18.4%), and AEs only (33, 
14.8%). Eighty-one (36.3%) patients transitioned overnight; 142 (63.7%) transitioned progressively 
over a mean of 21.5 days (median 21 days, range 3–70). Mean LEV dose at BRV initiation was 
1904.7±823.6 mg/day (median 2000, range 250–4000mg/day). At the end of follow-up, mean BRV 
dose was 173.2±823.6 mg/day (median 200, range 25–300mg/day). At 3 months, patients who 
transitioned progressively achieved numerically higher seizure-freedom (21.5% vs 18.9%) and 
responder (45.4% vs 35.1%) rates and reported less seizure worsening (6.9% vs 8.1%) compared with 
those who transitioned overnight; they also reported more AEs (28.2% vs 24.7%) and AEs that led to 
discontinuation (5.6% vs 1.2%).  
 
The improvement in seizure control among patients who switched because of poor efficacy was less 
than that observed in the overall population, while patients who switched because of poor 
tolerability, had similar results to the overall population in terms of tolerability. It should be 
emphasized that among the 53 patients who switched due to PAEs, 9 (17.0%) reported PAEs at 12 
months, and 3 (5.7%) discontinued because of PAEs; most (5/9) had previous psychiatric 
comorbidity. The most frequently reported PAEs were depression and irritability (both n=2, 3.8%). 
Outcomes are summarised in Table 4. 
 
Subgroup comparisons 
Full details of the subgroups and their treatment outcomes are summarised in Supplementary 
Material. Overall, effectiveness appeared to be better in patients with, than those without medical 
comorbidities. In contrast, outcomes were worse among patients with than those without LD. 
Brivaracetam tolerability was not highly impacted among patients with LD or psychiatric 
comorbidity, but was less well-tolerated by those with medical comorbidity. 
 
Outcomes of patients who had experienced a stroke (n=22) were compared with those of the 483 
patients who did not. A significantly greater proportion of patients in the stroke group were seizure-
free at 12 months compared with other patients (40.9% vs 17.5%; p=0.006). The proportion of 
patients reporting AEs was numerically higher in the group with stroke (50.5% vs 38.6%), but not 
those who discontinued due to AEs (4.5% vs 9.1%). 
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Subgroup analysis according to age showed that 57/575 (9.9%) patients were aged ≥65 years and 27 
switched treatment from LEV to BRV. Among patients aged ≥65 years, a significantly greater 
proportion were seizure-free (37.5% vs 15.3%; p<0.001) and responders (60.7% vs 37.4%; p<0.001) 
at 12 months compared with younger patients; incidences of AEs (42.1% vs 39.6%), and 
discontinuation due to AEs (14.0% vs 8.3) were numerically higher. Final BRV dosage was 
significantly lower among older than younger patients (median 100 vs 150 mg/day; p=0.003). 
 
DISCUSSION 
BRIVA-life was a retrospective analysis of data from 575 patients with focal epilepsy treated with 
BRV over 12 months. Most patients had DRE, as 89.3% had tried3 AEDs in the past. Brivaracetam 
was found to be effective in this large, difficult-to-treat population, with 40.0% of patients being 
responders and 17.2% seizure-free at 6 months and 39.7% and 17.5% at 12 months.  
 
These findings are generally consistent with those of other retrospective series. Three studies in 
particular were similar to the current study in terms of patient population.9–11 In two, 101 and 93 
patients with focal epilepsy (both 97%), who had failed 10 (median) and 6.3 (mean) previous AEDs, 
respectively, were included.10,11 At 6 months, responder and seizure-freedom rates were 27.8% and 
7.0% in one,10 and 35.1% and 8.8% in the other study.11 In a larger study (N=262), 87% of patients 
had focal epilepsy and had failed a mean of 4.4 AEDs (vs 7.9 in the current study); responder and 
seizure-freedom rates at 6 months were 40.5% and 15.3%, respectively.9 As with other AEDs, an 
inverse relationship between response and the number of lifetime AEDs was observed.18,19 
Responder rates in the current study were also consistent with those in the BRV RCTs. In an analysis 
of data pooled from three RCTs, responder rates were 34.2%, 39.5% and 37.8% for patients treated 
with 50, 100, or 200 mg/day,respectively.20 Seizure-freedom rates were considerably lower in the 
RCTs than in the current study; the highest, 5.1%, was observed in the 100 mg/day group.20  
However, any comparison of the results between the current study and the RCTs must be done with 
caution given the major differences in design and patient populations. 
 
Retention rate was 80.2% at 6 months, and 70.4% at 1 year. The 6-month retention rate was similar 
in the study by Steinert et al (78.5%),9 but lower in the study by Steinhoff et al (51.5%),10 most 
probably due to the inclusion of patients with more severe disease. One-year retention rates for 
other newer AEDs are similar to that obtained in this study, including eslicarbazepine (73.4%), 
perampanel (60.6%) and lacosamide (70%).21–23 These first long-term data for BRV obtained in a large 
series of patients in clinical practice emphasize the lack of a high rate of early withdrawal. 
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At 12 months, 39.8% of patients reported AEs, with 8.9% discontinuing due to AEs. These results are 
in keeping with findings of the three aforementioned retrospective series,9–11 and with those of a 
meta-analysis, which found BRV, LEV and  gabapentin to have the best tolerability profiles among 
newer AEDs.24 Adverse events reported by 5% of patients were somnolence, dizziness, headache, 
and fatigue in the BRV pivotal trials18 and somnolence, irritability, dizziness and fatigue in the current 
study. Importantly, no unexpected AEs, such as laboratory test and cardiac abnormalities, or DRESS 
syndrome, were observed.  
 
Psychiatric/behavioral AEs have been reported as one of the disadvantages of using LEV;25 therefore, 
PAEs were monitored closely in this study. At 12 months, 14.3% of patients reported PAEs; 0.7% 
cases were considered severe and 3.7% led to discontinuation. The most common PAE in the current 
report and in BRV RCTs was irritability; 6.6% and 3.2%, respectively.18 The higher incidence in this 
study is likely due to the large proportion of patients with psychiatric comorbidity (44.2%) – such 
patients are typically excluded from RCTs.26 Among 52 patients who switched from LEV because of 
PAEs, nine (17%) reported PAEs, and three (3.7%) discontinued because of PAEs. Reduction in PAEs 
among patients switching from LEV to BRV has been reported in an exploratory prospective study;27 
Hirsch et al also reported improved tolerability among patients who switched from LEV because of 
PAEs,14 while Steining et al reported improvement regardless of the switch reason. Differences in 
BRV and LEV PAE profiles could potentially be explained by the lack of interaction between BRV and 
inhibitory (GABA, glycine) or excitatory (glutamate) postsynaptic ligand-gated receptors, unlike LEV.5 
 
Median BRV dosage on the first day was 50 mg. Among patients not transitioning from LEV, seizure-
freedom at 3 months was significantly greater among those (26.7%) who reached target dosage on 
the first day than those who did not, while incidences of AEs and discontinuations due to AEs were 
similar. Titration, therefore, could be avoided for patients at high risk of breakthrough seizures and 
accidents, or those experiencing severe AEs requiring rapid AED replacement.28,29 
 
For patients who transitioned from LEV to BRV, a 1:10 ratio was used for those on a median LEV 
dosage ≤2000 mg/day; for those on >2000 mg/day, equivalence was not clear and a higher ratio 
(1:15) was used, as observed in other studies.9,14 More patients who switched overnight experienced 
seizure worsening than those who transitioned progressively (8.1% vs 6.9%). In contrast, those who 
transitioned progressively reported more AEs that led to discontinuation (7.7% vs 2.5%). This 
increase is likely due to overlapping of two AEDs (LEV and BRV) that share a similar mechanism of 
action,30 and an increase in the total drug load over the transition period (mean duration 21.5 
days).31 Therefore, overnight transition could be recommended for patients more susceptible to AEs, 
and progressive transition for those at risk of worsening. Seizure-freedom was also lower among 
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patients who had previous LEV exposure compared with LEV-naïve patients (13.4% vs 17.9%). 
Overall, these observations confirm that although previous LEV failure can affect response to BRV, 
treatment with BRV could still be of benefit for these patients. Predictors of seizure-freedom with 
BRV were absence of complex partial seizures at baseline, longer epilepsy duration, and fewer 
lifetime AEDs in a logistic regression analysis. 
 
Brivaracetam was less effective, but better tolerated by patients with than those without LD. These 
findings are similar to those of smaller studies that included patients with epileptic encephalopathies 
or LD.32,33 While classifying seizures in such patients may be challenging, results from the current and 
other studies (including  genetic generalized epilepsy) justify further exploration of the role of BRV in 
their treatment.12,30  The number of elderly patients and those with late-onset epilepsy continue to 
increase; therefore, data from these groups, frequently excluded from RCTs, are needed.34 
Brivaracetam showed promise in the treatment of elderly patients, as well as those who had 
experienced a stroke, the most frequent cause of late-onset epilepsy.35 
 
BRIVA-LIFE has limitations associated with its retrospective design; notably, the risk of missing 
relevant information from records, and lack of randomization and blinding, which may introduce 
bias. Its strength lies in its large sample size and long follow-up. Results showed that treatment with 
BRV was effective and well-tolerated, with no unexpected AEs over 12 months; PAEs were less 
frequent than with LEV. Treatment initiation without titration was feasible in some patients, as was 
a switch from LEV at a dose ratio of 1:10–15. Tolerability was not highly affected among patients 
with LD or psychiatric comorbidity. 
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Table 1 
Demographics and baseline disease characteristics of the study population (all values are based on 
the safety set, unless specified otherwise) . 
Characteristic 
Safety set 
N=575 
Sex, n (%)  
Female | Male 285 (49.6) |290 (50.4) 
Age at baseline, mean (range), years 41.9 (16–88) 
Age at baseline, n (%)  
<65 years | 65 years 518 (90.1%) | 57 (9.9%) 
Age at epilepsy onset, median (IQR), years 20 (10.0–34.8) 
Duration of epilepsy, median (IQR), years 14 (5.0–27.0) 
Number of monthly seizures 
Mean (SD) | Median (IQR) 
 
17.5 (45.7) | 5 (1.7–15.0) 
Type of seizures at baseline, n (%)
a
 
SP | CPS | Secondary generalised 
N=560 
132 (23.6) | 391 (69.8) | 181 (32.3) 
Aetiology, n (%) 
Cryptogenic | Cortical developmental malformation 
Mesial temporal sclerosis | Perinatal hypoxia 
Tumour | Vascular 
Trauma | Cavernoma 
Other 
215 (37.4) |  89 (15.5) 
58 (10.1) |  43 (7.5) 
35 (6.1)   |  25 (4.3) 
18 (3.1)   |  13 (2.3) 
79 (13.7) 
Number of previous AEDs  
Mean (range) | Median (IQR) 
N=525 
7.9 (1–19) | 8 (5–10) 
Number of concomitant AEDs  
Mean (range) | Median (IQR) 
Most frequently used concomitant AEDs, n (%)
b
 
Levetiracetam | Lacosamide 
Carbamazepine | Eslicarbazepine 
Lamotrigine | Perampanel 
N=574 
3 (0–6) | 3 (2–3) 
 
228 (39.7) | 178 (31.0) 
142 (24.7) | 138 (24.0)  
135 (23.5) | 131 (22.8) 
Number of previous AEDs  
Mean (range) | Median (IQR) 
Number of previous AEDs, n (%) 
1–3 | 4–6  
7–9 | 10–12  
≥13 
N=525 
7.9 (1–19) | 8 (5–10) 
 
56 (10.7)   | 153 (29.1) 
157 (29.9) | 100 (19.0) 
59 (11.2) 
Levetiracetam treatment status, n (%) 
Prescribed at baseline|Previous exposure
c
|Naïve 
 
228 (39.7) | 419 (79.8) | 106 (20.2) 
Previous medical comorbidity, n (%) 
Hypertension | Obesity 
Migraine | Stroke | Diabetes 
N=483 |127 (26.3) 
59 (12.2) | 36 (7.5) 
28 (5.8)  | 22 (4.6) | 14 (2.9) 
Previous psychiatric comorbidity, n (%) 
Depression | Anxiety 
Personality disorder | Hyperactivity 
Psychosis | Other 
N=522 | 244 (44.2) 
112 (20.3) |  97 (17.6) 
32 (5.8)   |  29 (5.3) 
18 (3.3)   |  35 (6.3) 
Learning disability, n (%) N=570 | 182 (31.9) 
a
Patients could report >1 seizure type;
 b
 Patients could be on >1 concomitant AED; 
c 
Before or at 
baseline 
AED=antiepileptic drug; CPS=Complex partial; IQR=interquartile range; SD=standard deviation, 
SP=simple partial 
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Table 2 
Summary of safety outcomes (safety set, N=575). 
 
3 months 6 months 12 months 
Adverse events, n (%) 
Any AE 160 (27.8) 210 (36.5) 229 (39.8) 
Mild 64 (11.1) 84 (14.6) 86 (15.0) 
Moderate 69 (12.0) 94 (16.3) 110 (19.1) 
Severe 11 (1.9) 12 (2.1) 14(2.4) 
Not classified 16 (2.8) 20 (3.5) 19 (3.3) 
AEs leading to discontinuation 27 (4.7) 44 (7.7) 51 (8.9) 
Psychiatric adverse events, n (%) 
Any AE 52 (9.0) 73 (12.7) 82 (14.3) 
Mild 19 (3.3) 30 (5.2) 35 (6.1) 
Moderate 25 (4.3) 33 (5.7) 36 (6.3) 
Severe 4 (0.7) 4 (0.7) 4 (0.7) 
Not classified 4 (0.7) 6 (1.0) 7 (1.2) 
AEs leading to discontinuation 10 (1.7) 17 (3.0) 21 (3.7) 
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Table 3  
Frequently-reported adverse events (reported by ≥1% of patients). 
Adverse event, n (%) 
Safety population 
N=575 
Somnolence 65 (11.3) 
Irritability 38 (6.6) 
Dizziness 36 (6.3) 
Fatigue 35 (6.1) 
Memory disturbances 27 (4.7) 
Verbal aggressiveness 19 (3.3) 
Anxiety 16 (2.8) 
Headache 14 (2.4) 
Insomnia 14 (2.4) 
Depression 13 (2.3) 
Physical aggressiveness 10 (1.7) 
Nausea and vomiting 6 (1.0) 
 
AEs reported by <1% pf patients: weight increase (n=4, 0.7%), hyporexia (n=3, 0.5%), ataxia, mouth 
disturbances, attention disturbances, tongue paresthesia, suicidal ideation, erectile disfunction, behavioral 
disturbances, myalgias, myoclonic jerks (all n=2, 0.3%), allopecia, visual hallucinations, anorexia, appetite 
increase, tics, falls, cold, renal colic, confusion, respiratory depression, urninary disturbances, skin 
disturbances, psychosis, dysgeusia, stomach pain, constipation, gingivorrhagia, hypersalivation, restlessness, 
nervoussness, libido disturbances, weight loss, influenza, phonophobia, cough and blurred vision (all n=1, 
0.2%). 
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Table 4 
Seizure-related and safety outcomes among patients who switched treatment from levetiracetam to 
brivaracetam and according to reason for switch. 
 
 3 months 6 months 12 months 
Switch overall, n (%) 
Seizure-related outcomes n=204 n=220 n=221 
Seizure-free 42 (20.6) 44 (20.0) 50 (22.6) 
Responders 85 (41.7) 87 (39.5) 99 (44.8) 
Improvement 119 (58.3) 127 (57.7) 121 (54.8) 
Worsening 15 (7.4) 23 (10.5) 25 (11.3) 
Safety outcomes n=223 n=223 n=223 
Any AE 60 (26.9) 79 (35.4) 86 (38.6) 
Discontinuation due to AEs 9 (4.0) 16 (7.2) 19 (8.5) 
Switch due to lack of efficacy, n (%) 
Seizure outcomes n=171 n=185 n=185 
Seizure-free 20 (11.7) 21 (11.4) 24 (13.0) 
Responders 61 (35.7) 61 (33.0) 70 (37.8) 
Improvement 95 (55.6) 100 (51.4) 92 (49.7) 
Worsening 14 (8.2) 21 (11.4) 24 (13.0) 
Safety outcomes n=186 n=186 n=186 
Any AE 44 (23.7) 62 (33.3) 68 (36.6) 
Discontinuation due to AEs 4 (2.2) 7 (3.8) 9 (4.8) 
Switch due to adverse events, n (%) 
Seizure outcomes n=70 n=71 n=72 
Seizure-free 27 (38.6) 29 (40.8) 31 (43.1) 
Responders 37 (52.9) 36 (50.7) 42 (58.3) 
Improvement 49 (70.0) 47 (66.2) 47 (65.3) 
Worsening 3 (4.3) 7 (9.9) 9 (12.5) 
Safety outcomes n=74 n=74 n=74 
Any AE 33 (44.6) 36 (48.6) 37 (50.0) 
Discontinuation due to AEs 7 (9.5) 10 (13.5) 12 (16.2) 
Switch due to psychiatric adverse events, n (%) 
Seizure outcomes n=51 n=51 n=52 
Seizure-free 25 (49.0) 26 (51.0) 29 (55.8) 
Responders 33 (64.7) 32 (62.7) 36 (69.2) 
Improvement 40 (78.4) 39 (76.5) 38 (73.1) 
Worsening 1 (2) 4 (7.8) 6 (11.5) 
Safety outcomes n=53 n=53 n=53 
Any AE 20 (37.7) 21 (39.6) 22 (41.5) 
Discontinuation due to AEs 3 (5.7) 4 (7.5) 5 (9.4) 
Any psychiatric AE 
Mild 
Moderate 
Severe 
7 (13.3) 
3 (5.7) 
3 (5.7) 
1 (1.9) 
8 (15.1) 
3 (5.7) 
4 (7.5) 
1 (1.9) 
9 (17.0) 
4 (7.5) 
4 (7.5) 
1 (1.9) 
Discontinuation due to psychiatric AEs 2 (3.8) 2 (3.8) 3 (5.7) 
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Subgroup comparisons 
Of 570 patients, 182 (31.9%) reported learning disability (LD). Data on presence of medical 
comorbidities were available for 483 patients, with 127 (26.3%) reporting comorbidities. Similarly, 
data on presence of psychiatric comorbidities were available for 483 patients, with 244(44.2%) 
reporting comorbidities. A comparison of baseline characteristics and study outcomes between the 
groups of patients with and without comorbidities are presented in Table S1.  
 
Predictive factors for seizure freedom 
A binary logistic regression analysis was performed to determine factors predictive of seizure-
freedom at the end of the 12-month observation period.  
 
Baseline characteristics of the population were analysed according to seizure- and safety-related 
results. The Student t test (or the Mann-Whitney U test) and the chi-square test (or Fisher's exact 
test) were used depending on the nature of the variables. Once potential relationships between the 
baseline variables with the response/adverse effects was determined, those with p<0.10 were 
selected to construct the model. 
 
The following variables were selected for inclusion in the model  to predict seizure-freedom: patient 
age (p<0.001), age of onset of epilepsy (p<0.001), epilepsy duration (p<0.001), vascular etiology 
(p<0.001), mesial temporal sclerosis etiology (p=0.027), cortical developmental malformation 
etiology (p = 0.024), learning disability (p=0.001), presence of any medical comorbidity (p=0.009), 
number of medical comorbidities (p=0.002), hypertension (p<0.001), stroke (p=0.006), diabetes 
(p=0.002), concern about the disease (p=0.002), presence of seizures at onset (p <0.001), seizure 
frequency at baseline (p<0.001), simple partial seizure frequency at baseline (p<0.001),complex 
partial seizures (CPS) at baseline (p<0.001), CPS frequency at baseline (p<0.001), secondary 
generalised seizure frequency at baseline (p<0.001), number of previous AEDs (p<0.001), number of 
concomitant AEDs at baseline (p<0.001). 
 
The best resulting model contained three variables: duration of epilepsy, CPS at baseline, and 
number of previous AEDs (Table S2). In terms of epilepsy duration, the longer the duration, the 
greater the likelihood of seizure-freedom. The presence of CPS seizures at baseline was also found to 
influence seizure freedom – patients not reporting CPS baseline had a greater chance of seizure-
freedom at follow-up. Finally, the fewer lifetime AEDs the patients had taken, the greater the 
likelihood of seizure-freedom. A valid multivariate binary logistic regression model with variables 
based on adverse effects could not be performed. 
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